<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04330287</url>
  </required_header>
  <id_info>
    <org_study_id>14-5874-BO</org_study_id>
    <nct_id>NCT04330287</nct_id>
  </id_info>
  <brief_title>HIV-HEART Aging Study (15 Year Follow up)</brief_title>
  <acronym>HIV-HEART</acronym>
  <official_title>A Prospective, Epidemiologic and Multicentre Trial to Determine the Cardiovascular Risk, New Cardiovascular Events and the Cardiovascular Diseases in HIV-infected Patients: 15 Year Follow up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HIV/HEART Aging study (HIVH) is an ongoing, prospective, multicentre trial that was
      conducted to assess the incidence, the prevalence and the clinical course of cardiovascular
      diseases (CVD) in HIV-infected patients. The study population includes outpatients from
      specialized HIV-care units of the German Ruhr region, who were at least 18 years of age, were
      known to have a HIV-infection and exhibited a stable disease status within 4 weeks before
      inclusion into the trial. From March 2004 (Pilot phase) to October 2022 (15 year Follow-up)
      1806 HIV+ patients were recruited in a consecutive manner. The standardised examinations
      included a targeted assessment of medical history and physical examination. Blood was drawn
      for comprehensive laboratory tests including HIV specific parameters (CD4 cell count, HIV-1
      RNA levels) and cardiovascular items (lipid concentrations, BNP values and renal parameters).
      Furthermore, non-invasive tests were performed during the initial visit, including additional
      heart rate and blood pressure measurements, electrocardiogram (ECGs) and transthoracic
      echocardiography (TTE). Examinations were completed in accordance with previously defined
      standard operating procedures. CVD were defined as coronary, cerebrovascular, peripheral
      arterial disease, heart failure or cardiac vitium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A comprehensive detailed description of the study procedures had been previously published
      (European Journal of medical research 2007;12:243-248).

      Comprehensive non invasive cardiovascular examination

        -  Anamnesis

        -  File recherche,Physical examination

        -  Documentation of the cardiovascular and antiretroviral medical therapy

        -  Electrocardiogram

        -  Transthoracic echocardiography

        -  Exercise electrocardiogram

        -  Exercise Montreal Cognitive Assessment test

        -  Exercise the Grooved Pegboard test

        -  Blood and stool sample collection

        -  Questionnaire to quality of life and health economics
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of frequency, severity of cardiovascular diseases - especially of coronary artery disease - in patients with HIV-Infection</measure>
    <time_frame>Baseline up to 15 year follow up</time_frame>
    <description>Calculation of the Framingham Risk Score. It was assumed, that in the next 10 years the individual cardiovascular risk varies between maximal 20% and minimal 0%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of progression of cardiovascular diseases - especially of coronary artery disease - in patients with HIV-Infection</measure>
    <time_frame>Baseline up to 15 year follow up</time_frame>
    <description>Calculation of Odds Ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact on cardiovascular risk on amount of atherosclerosis</measure>
    <time_frame>Baseline up to 15 year follow up</time_frame>
    <description>in relation to age, gender and classic cardiovascular rsik factors inter alia smoking, diabetes, hypercholesterinaemia and arterial hypertension by calculating the relative risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on life quality</measure>
    <time_frame>Baseline up to 15 year follow up</time_frame>
    <description>in relation to HIV-specfic cardiovascular rsik factors including inter alia virus load (copies/ml) in combination with CD4-count and duration of HV-Infection by calculating the standard deviation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on life quality</measure>
    <time_frame>Baseline up to 15 year follow up</time_frame>
    <description>in relation to HIV-specfic cardiovascular rsik factors including inter alia CD4-count (cells/mm3) in combination with virus load and duration of HIV-infection by calculating the standard deviation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on life quality</measure>
    <time_frame>Baseline up to 15 year follow up</time_frame>
    <description>in relation to HIV-specfic cardiovascular rsik factors including inter alia duration of HIV-Infection (in years) in combination with virus load and CD4-count by calculating the standard deviation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on cardiovascular risk, amount of atherosclerosis and life quality</measure>
    <time_frame>Baseline up to 15 year follow up</time_frame>
    <description>in relation to cardiovascular and antiretroviral medication by calculating the 95%-Confidence interval</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>HIV Infections</condition>
  <condition>Coronary Disease</condition>
  <condition>Myocardial Infarction</condition>
  <condition>HIV Encephalopathy</condition>
  <condition>Aging</condition>
  <condition>Heart Failure</condition>
  <condition>Weight Gain</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      stored blood and stool samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        population affected by HIV
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Known HIV-infection

          -  Signed informed consent

        Exclusion Criteria:

          -  Acute cardiovascular disease

          -  Unstable hemodynamic status in the three weeks before inclusion

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stefan Esser, PD MD</last_name>
    <phone>00492017233878</phone>
    <phone_ext>-3845</phone_ext>
    <email>stefan.esser@uk-essen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Albayrak-Rena</last_name>
    <phone>004920172383721</phone>
    <phone_ext>3631</phone_ext>
    <email>sarah.albayrak-rena@uk-essen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut für Medizinische Informatik, Biometrie und Epidemiologie</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik für Dermatologie</name>
      <address>
        <city>Essen</city>
        <state>Nordrheinwestfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Esser, MD</last_name>
      <phone>0201/723-3878</phone>
      <email>stefan.esser@uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Albayrak-Rena</last_name>
      <phone>0201/723-83721</phone>
      <email>sarah.albayrak-rena@uk-essen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>HIV physician pratice</name>
      <address>
        <city>Duisburg</city>
        <state>NRW</state>
        <zip>47259</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Friedhelm Kwirant, MD</last_name>
      <phone>0049203782173</phone>
      <email>FKwirant@t-online.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bochum, Department of Dermatology</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norbert Brockmeyer, MD</last_name>
      <phone>++49 234 509 3471</phone>
      <email>n.brockmeyer@derma.de</email>
    </contact>
    <contact_backup>
      <last_name>Anja Potthoff, MD</last_name>
      <phone>++49 0234/509-1</phone>
      <email>a.potthoff@klinikum-bochum.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>HIV Outpatient Department</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Hower, MD</last_name>
      <phone>++49 95320700</phone>
      <email>ID.ambulanz@klinikumdo.de</email>
    </contact>
    <contact_backup>
      <last_name>Claudia Bachmann, Study nurse</last_name>
      <phone>++49 95320700</phone>
      <email>ID.ambulanz@klinikumdo.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 30, 2020</study_first_submitted>
  <study_first_submitted_qc>March 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>Stefan Esser M.D.</investigator_full_name>
    <investigator_title>PD M.D. Head of HPSTD Ambulance, University Hospital, Essen, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <keyword>Aging</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>coronary heart desease</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>HIV-associated neurocognitive disorders</keyword>
  <keyword>weight gain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>AIDS Dementia Complex</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

